Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits.
Long-term exposure to the psychotomimetic drug phencyclidine produces prefrontal cortical cognitive and dopaminergic dysfunction in rats and monkeys, effects possibly relevant to the frontal cortical impairments of schizophrenia. In the present study, the effects of subchronic phencyclidine administration (0.3 mg/kg twice-daily for 14 days) on monoamine systems in the monkey brain were examined and related to cognitive performance on an object retrieval/detour task, which has been linked with frontostriatal function. Long-term (14 days) administration of phencyclidine resulted in a marked and persistent reduction in dopamine utilization in the frontal cortex. Moreover, the degree of cognitive impairment in phencyclidine-treated monkeys correlated significantly with the magnitude of dopaminergic inhibition within the dorsolateral prefrontal cortex and prelimbic cortex. No specific correlation was measured for dopamine utilization in other cortical regions or for indices of serotonin transmission in any brain region. These data show that repeated exposure to phencyclidine reduces prefrontal cortical dopamine transmission, and this inhibition of dopaminergic function is associated with performance impairments on a task sensitive to frontostriatal cognitive dysfunction. Thus, the cognitive deficits of phencyclidine-treated monkeys, as in schizophrenia, appear to be mediated, in part, by reduced dopaminergic function in specific subregions of the frontal cortex.
Jentsch
J D
JD
Section of Neurobiology, Yale University of School of Medicine, New Haven, Connecticut, USA.
Taylor
J R
JR
Elsworth
J D
JD
Redmond
D E
DE
Roth
R H
RH
D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism; D002522:Chlorocebus aethiops; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000139:chemically induced* / Q000503:physiopathology; D003342:Corpus Striatum / Q000503:physiopathology*; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D005260:Female; D005625:Frontal Lobe / Q000378:metabolism / Q000503:physiopathology*; D006213:Hallucinogens / Q000494:pharmacology*; D008297:Male; D010622:Phencyclidine / Q000494:pharmacology*; D012701:Serotonin / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects*; D013997:Time Factors
D015306:Biogenic Monoamines; D006213:Hallucinogens; D012701:Serotonin; D010622:Phencyclidine; D004298:Dopamine